Typbar-TCV is a Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine. Typbar-TCV is the world's 1st clinically proven conjugate typhoid vaccine.
Typbar TCV is indicated as a preventative vaccine against Typhoid which is caused by Salmonella Typhi and Paratyphi.
The WHO recently recommended that routine childhood immunization programs include Typbar TCV as a single intramuscular dose for primary vaccination of infants and children from 6 months of age.
It is also recommended for adults ≤45 years of age and in catch-up campaigns in children ≤15 years of age in typhoid-endemic regions.
Clinical Trial NCT03600025: Cellular Immune Responses in Typhoid Fever Patients and Vaccinees (Recruiting)
- This Phase 1 clinical trial is to further understand the role of mucosal-associated invariant T cell (MAIT) and natural killer (NK) cell responses in typhoid fever or following vaccination.
- Transcriptome profiling of human immune responses to S. Typhi infection is not clearly understood.
- Establishing successful infection by S. Typhi evasion of T cell and neutrophil responses need to be investigated to better understand the correlates of protection.